Lifetime Sciences employs advanced technologies to enhance patient care through precision medicine. One of their key offerings is the MyPGt™ test, which utilizes pharmacogenomics to identify the most effective medications and dosages for individual patients. This approach aims to minimize adverse drug reactions and improve treatment efficacy, ultimately leading to more personalized and cost-effective healthcare solutions. Additionally, the company utilizes quantitative Real-Time PCR (RT-PCR) technology for infectious disease testing, allowing for rapid and accurate pathogen detection, including the identification of antibiotic resistance.

In the realm of genetics, Lifetime Sciences offers Cardio Genetics testing, which analyzes a patient's genetic profile to assess predispositions to various cardiac conditions. This advanced diagnostic approach enables healthcare providers to tailor treatment plans based on genetic insights, thereby improving patient outcomes. Overall, Lifetime Sciences is committed to leveraging innovative technologies to facilitate the transition to precision-guided medicine, enhancing the quality of care for patients across various medical disciplines.

United States

Lifetime Sciences (formerly MyGenetx) is a CLIA-certified and CAP accredited lab focused on molecular and advanced diagnostic testing. Lifetime Sciences is the primary resource for transitioning and implementing precision guided medicine. Our medical team consists of experts in research and clinical product development for genetics.  

MyPGt™
A pharmacogenetic panel to determine how you metabolize your medication(s).  Traditional "one size fits all"​ dosing strategies can cause adverse drug reactions or drug inefficacy.

MyHap2™
A proprietary genetic test to determine heart attack risk in patients with diabetes.

Lifetime Sciences

Company Details